Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

https://www.thelancet.com/collections/neurology?dgcid=hubspot_email_infocusalerts-neurology_feature&parent=001585&startPage=&ContentItemType=fla&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-99VwkkTlDbmJwN4z4gyU50hTCekDZNXXnyiM64IZJbgqO8oP8l9eyICcTTagXk44tp2RlcnXtblAqHlE4lGb90gTjKyw&_hsmi=326638970&utm_content=325812895&utm_source=hs_email